ライフサイエンスコーパス: dopamine beta-hydroxylase

1 s-responsive genes, tyrosine hydroxylase and dopamine beta-hydroxylase.

2 reactivity for choline acetyltransferase and dopamine beta-hydroxylase.

3 naline by inactivating the gene that encodes dopamine beta-hydroxylase.

4 or ligands, due to a disruption the gene for dopamine beta-hydroxylase.

5 eneration of norepinephrine from dopamine by dopamine beta-hydroxylase.

6 ted to myenteric ganglia by the promoter for dopamine beta-hydroxylase.

7 ogous to the N-terminal regulatory region of dopamine beta-hydroxylase.

8 e oxidase, ceruloplasmin, lysyl oxidase, and dopamine beta-hydroxylase.

9 es directed against tyrosine hydroxylase and dopamine-beta-hydroxylase.

10 nthesizing enzymes, tyrosine hydroxylase and dopamine-beta-hydroxylase.

11 Analyses of noradrenergic (dopamine-beta-hydroxylase) afferents revealed no differe

12 rving as a cofactor to superoxide dismutase, dopamine-beta-hydroxylase, amyloid precursor protein, ce

13 and consequent lipolysis, as do knockouts of dopamine beta-hydroxylase, an enzyme required for catech

14 nce for the noradrenergic transmitter enzyme dopamine beta-hydroxylase and by using catecholamine his

15 ased the density of axons immunoreactive for dopamine beta-hydroxylase and for serotonin.

16 found to coexist at significant levels with dopamine beta-hydroxylase and hence it is likely that th

17 orms of granule membrane proteins, including dopamine beta-hydroxylase and peptidyl glycine alpha-ami

18 Recent evidence has shown that the genes for dopamine beta-hydroxylase and the dopamine transporter S

19 For the catecholamine biosynthetic enzymes, dopamine beta-hydroxylase and tyrosine hydroxylase, regu

20 press the adrenergic differentiation markers dopamine beta-hydroxylase and tyrosine hydroxylase.

21 criptional complex that drives expression of dopamine-beta-hydroxylase and can also up-regulate expre

22 r these substances as well as for serotonin, dopamine-beta-hydroxylase and met-enkephalin are observe

23 zed by dual immunohistochemical detection of dopamine-beta-hydroxylase and PRV.

24 on microscopic levels to investigate whether dopamine-beta-hydroxylase and tyrosine hydroxylase-conta

25 Direct evidence for the termination of dopamine-beta-hydroxylase and tyrosine hydroxylase-posit

26 ctive (TH-ir) axons in the PF also expressed dopamine-beta-hydroxylase and were therefore noradrenerg

27 essary but also sufficient to induce Phox2b+ dopamine-beta-hydroxylase+ and tyrosine hydroxylase+ NA

28 pment, while inhibitors of aminopeptidase A, dopamine beta-hydroxylase, and the intestinal Na(+)/H(+)

29 ds of cells expressing tyrosine hydroxylase, dopamine-beta-hydroxylase, and the SA lineage marker SA-

30 Dopamine-beta-hydroxylase- and tyrosine hydroxylase-posi

31 ats was achieved by intrathecal injection of dopamine beta-hydroxylase antibodies conjugated to the t

32 ion in response to psychological stress.Anti-dopamine-beta-hydroxylase antibody conjugated to the neu

33 njections (spinal segments T2-T3) of an anti-dopamine-beta-hydroxylase antibody conjugated to the rib

34 ls with cAMP, protein complexes bound to the dopamine beta-hydroxylase AP1/cAMP response element elem

35 reactive to PHA-L, tyrosine hydroxylase, and dopamine beta-hydroxylase, but not phenylethanolamine-N-

36 titative analysis of immunocytochemistry for dopamine beta-hydroxylase, choline acetyltransferase, an

37 from 2DG-injected rats pretreated with anti-dopamine-beta-hydroxylase conjugated to saporin to lesio

38 We have shown that an antibody to dopamine-beta-hydroxylase conjugated with saporin (anti-

39 opsin2(ChR2)-mCherry (AAV2) into the RVLM of dopamine-beta-hydroxylase Cre transgenic mice (DbetaH(Cr

40 2-mCherry unilaterally into the brainstem of dopamine-beta-hydroxylase(Cre/0) mice.

41 Dopamine-beta-hydroxylase (D beta H) catalyzes the conve

42 in, coupled to the antibody directed against dopamine beta hydroxylase (DbetaH-saporin), the analgesi

43 le increase in tyrosine-hydroxylase (TH) and dopamine beta-hydroxylase (DbetaH) immunoreactive (IR) a

44 latory actions on tyrosine hydroxylase (TH), dopamine beta-hydroxylase (DbetaH), and the norepinephri

45 omatostatin and tyrosine hydroxylase (TH) or dopamine beta-hydroxylase (DbetaH), respectively.

46 enzyme involved in catecholamine metabolism, dopamine beta-hydroxylase (DbetaH), which converts dopam

47 Quantification of dopamine beta-hydroxylase (DbetaH)-immunostained varicos

48 s carried out to investigate overlap between dopamine-beta-hydroxylase (DbetaH) -immunopositive proje

49 binding protein (pCREB) expressing nuclei in dopamine-beta-hydroxylase (DbetaH) containing cells in t

50 C noradrenergic neurons were demonstrated by dopamine-beta-hydroxylase (DbetaH) immunofluorescence.

51 Dopamine-beta-hydroxylase (DbetaH) is a copper-containin

52 of Ret (Ret(MEN2B)) under the control of the dopamine-beta-hydroxylase (DbetaH) promoter develop prof

53 We used the human dopamine-beta-hydroxylase (DbetaH) promoter to direct tr

54 tein (EGFP) under the control of a synthetic dopamine-beta-hydroxylase (DbetaH) promoter was used to

55 or and the catecholamine-synthesizing enzyme dopamine-beta-hydroxylase (DbetaH) was performed using c

56 ciated viral vectors into the brain of adult dopamine-beta-hydroxylase (DbetaH)(Cre/0) mice.

57 transporter 2 (VMAT2), serotonin (5-HT), and dopamine-beta-hydroxylase (DbetaH; a marker for norepine

58 le cellular tasks, ATP7A transfers copper to dopamine beta hydroxylase (DBH) within the lumen of the

59 -function dramatically reduces expression of Dopamine Beta Hydroxylase (Dbh), a gene encoding a cruci

60 e visualized by immunoperoxidase labeling of dopamine beta hydroxylase (DbH), and gastric preautonomi

61 , those that express the NA synthetic enzyme dopamine beta hydroxylase (DbH)] in the caudal NST were

62 % of the total phenotypic variance in plasma dopamine beta-hydroxylase (DBH) activity in samples from

63 ning them were exposed to antibodies against dopamine beta-hydroxylase (DBH) and 5-HT.

64 NE synthesis, tyrosine hydroxylase (TH) and dopamine beta-hydroxylase (DBH) are absent.

65 Dopamine beta-hydroxylase (DBH) catalyzes the conversion

66 Dopamine beta-hydroxylase (DBH) catalyzes the production

67 Human norepinephrine (NE) deficiency (or dopamine beta-hydroxylase (DBH) deficiency) is a rare co

68 ble for normal tyrosine hydroxylase (TH) and dopamine beta-hydroxylase (DBH) expression in sympatheti

69 To examine if Egr1 also regulates dopamine beta-hydroxylase (DBH) gene expression, PC12 ce

70 The dopamine beta-hydroxylase (DBH) gene is expressed select

71 e investigated by targeted disruption of the dopamine beta-hydroxylase (Dbh) gene, thereby eliminatin

72 ) were created by targeted disruption of the dopamine beta-hydroxylase (DBH) gene.

73 tablished in vitro by retrograde tracing and dopamine beta-hydroxylase (DBH) immunocytochemistry.

74 biosynthetic genes tyrosine hydroxylase and dopamine beta-hydroxylase (DBH) is regulated by cell typ

75 Dopamine beta-hydroxylase (DBH) is the biosynthetic enzy

76 deficiency in an AD mouse model, we crossed dopamine beta-hydroxylase (DBH) knockout mice with amylo

77 We previously showed that ethanol regulates dopamine beta-hydroxylase (DBH) mRNA and protein levels

78 Tyrosine hydroxylase (TH) and dopamine beta-hydroxylase (DBH) mRNA expression in postm

79 Inhibition of dopamine beta-hydroxylase (DBH) results in a decrease in

80 hetic enzymes, tyrosine hydroxylase (TH) and dopamine beta-hydroxylase (DBH) was examined.

81 In mice lacking dopamine beta-hydroxylase (DBH), an enzyme critical for

82 al peptide (VIP), tyrosine hydroxylase (TH), dopamine beta-hydroxylase (DBH), and muscarinic and alph

83 at the neurotransmitter synthesizing enzyme, dopamine beta-hydroxylase (DBH), could selectively destr

84 ary expresses both the genes encoding TH and dopamine beta-hydroxylase (DBH), the key enzymes in nore

85 nergic neurons by inducing the expression of dopamine beta-hydroxylase (DBH), the terminal enzyme for

86 the CB1 receptor population specifically in dopamine beta-hydroxylase (DBH)-expressing cells is both

87 ify cholecystokinin (CCK) and noradrenergic, dopamine beta-hydroxylase (DBH)-expressing NTS neurons a

88 iosynthetic enzymes tyrosine hydroxylase and dopamine beta-hydroxylase (DBH).

89 sed with the norepinephrine-synthetic enzyme dopamine beta-hydroxylase (DBH).

90 Gal-immunoreactive fibers did not co-contain dopamine beta-hydroxylase (DBH).

91 is a clear sequence homologue of the enzyme dopamine beta-hydroxylase (DBH).

92 )-diaphorase, tyrosine hydroxylase (TH), and dopamine beta-hydroxylase (DBH).

93 otypes of mice lacking NE due to mutation of dopamine beta-hydroxylase (dbh).

94 putative monooxygenase with low homology to dopamine beta-hydroxylase (DBH).

95 By comparing the number and distribution of dopamine beta-hydroxylase (DBH)/cholinergic appositions,

96 Ethanol treatment elevated dopamine beta-hydroxylase (DBH, EC 1.14.17.1) mRNA and p

97 question genetically by using mice that lack dopamine beta-hydroxylase (dbh-/- mice).

98 Gene-targeted mice that lack dopamine beta-hydroxylase (dbh-/-), the enzyme needed to

99 of endogenous tyrosine hydroxylase (TH) and dopamine-beta hydroxylase (DBH) gene expression in these

100 Finally, immunohistochemical staining of dopamine-beta-hydroxylase (DBH) containing cells confirm

101 Dopamine-beta-hydroxylase (DBH) is the penultimate enzym

102 produce a targeted gene knockdown of NPY and dopamine-beta-hydroxylase (DBH), a catecholamine biosynt

103 here the immunocytochemical distribution of dopamine-beta-hydroxylase (DBH), a noradrenergic marker,

104 immunoreactive neurons was also labeled for dopamine-beta-hydroxylase (DBH), an enzyme involved in n

105 tudy compared the distribution and number of dopamine-beta-hydroxylase (DBH)- and phenylethanolamine-

106 eptide (VIP), tyrosine hydroxylase (TH), and dopamine-beta-hydroxylase (DBH).

107 i-enzymatic pathway that includes the enzyme dopamine-beta-hydroxylase (DBH).

108 ation of the norepinephrine synthetic enzyme dopamine-beta-hydroxylase (DBH).

109 eage products (tyrosine hydroxylase, Th, and dopamine beta-hydroxylase, Dbh) are markedly altered.

110 (encoding tyrosine hydroxylase, Th) and Dbh (dopamine beta-hydroxylase, Dbh) mRNA, whereas several ot

111 on 3 young patients with recently documented dopamine beta-hydroxylase deficiency at a single institu

112 We tested this hypothesis in vivo using dopamine beta-hydroxylase-deficient mice (DBH -/-), whic

113 Dopamine beta-hydroxylase-deficient mice (Dbh-/-), lacki

114 orin toxin conjugated to an antibody against dopamine beta hydroxylase (DSAP) was microinjected bilat

115 tity to the evolutionarily related mammalian dopamine beta-hydroxylase enzyme.

116 addition to the role of c-Fos in regulating dopamine beta-hydroxylase gene expression in response to

117 The 5'-flanking -1012C --> T variant of the dopamine beta-hydroxylase gene was slightly increased an

118 pinephrine due to targeted disruption of the dopamine beta-hydroxylase gene, Dbh, were used to critic

119 ional activation of tyrosine hydroxylase and dopamine beta-hydroxylase genes after repeated episodes

120 In addition, dopamine-beta-hydroxylase immunohistochemistry, employed

121 Previous studies have demonstrated dopamine-beta-hydroxylase immunoreactive (DBH-ir) fibers

122 of the A15 dorsal group and the very sparse dopamine-beta-hydroxylase immunoreactive fibers and vari

123 d, only tyrosine hydroxylase fibers, and not dopamine-beta-hydroxylase immunoreactive fibers, were lo

124 No dopamine-beta-hydroxylase immunoreactive perikarya were

125 Dopamine beta-hydroxylase-immunoreactive sympathetic ner

126 the density of tyrosine hydroxylase- but not dopamine-beta-hydroxylase-immunoreactive axons in sensor

127 Both tyrosine hydroxylase- and dopamine-beta-hydroxylase-immunoreactive fibers and punc

128 both tyrosine hydroxylase-immunoreactive and dopamine-beta-hydroxylase-immunoreactive) were also quan

129 ntaining tyrosine hydroxylase perikarya, but dopamine-beta-hydroxylase immunoreactivity was very spar

130 ed lower activities of monoamine oxidase and dopamine beta hydroxylase in the hippocampus and prefron

131 both noradrenaline (NA) and NA-synthesizing dopamine beta-hydroxylase in the peripheral nervous syst

132 le responses to male song and the density of dopamine-beta-hydroxylase in area X and another song nuc

133 assaying axons immunoreactive for the enzyme dopamine-beta-hydroxylase in representative areas of acu

134 These neurons were immunopositive for dopamine beta-hydroxylase, indicating that they were cat

135 ent and showed previously that the selective dopamine beta-hydroxylase inhibitor, nepicastat, had no

136 ented here examined tyrosine hydroxylase and dopamine-beta-hydroxylase innervation in hormonally inta

137 NPY knock-out (NPY KO) and dopamine beta-hydroxylase knock-out (DBH KO) mice that l

138 Here, we exposed dopamine beta-hydroxylase knock-out (Dbh(-/-)) mice, whi

139 sting by telemetrically monitoring the Tb of dopamine beta-hydroxylase knock-out (Dbh-/-) mice, which

140 etion on ethanol-mediated behaviors by using dopamine beta-hydroxylase knockout (Dbh -/-) mice that s

141 Additionally, dopamine beta-hydroxylase knockout (Dbh(-)(/)(-)) mice t

142 vement tests and examining motor deficits in dopamine beta-hydroxylase knockout (Dbh-/-) mice that la

143 psychostimulant responses by testing LRA in dopamine beta-hydroxylase knockout (Dbh-/-) mice that la

144 rmed transverse aortic constriction (TAC) in dopamine beta-hydroxylase knockout mice (Dbh(-/-), genet

145 d after treatment with NE inhibitors, and in dopamine beta-hydroxylase knockout mice (which cannot sy

146 This genomic region harbors monooxygenase dopamine beta-hydroxylase-like 1 gene (MOXD1), implicate

147 In a separate study, TH-ir and dopamine-beta-hydroxylase-like immunoreactivity (DBH-ir)

148 ing in vitro, and cAMP- and Phox2a-dependent dopamine-beta-hydroxylase-luciferase reporter expression

149 Dopamine beta-hydroxylase (-/-) mice are unable to synth

150 Seizure susceptibility was determined in the dopamine beta-hydroxylase null mutant (Dbh -/-) mouse us

151 immunotoxin, saporin-conjugated antiserum to dopamine-beta-hydroxylase, on acute restraint stress-ind

152 were used to investigate the distribution of dopamine-beta-hydroxylase- or tyrosine-hydroxylase-label

153 tyrosine hydroxylase, L-dopa decarboxylase, dopamine beta-hydroxylase, phenylethanolamine-N-methyltr

154 to demonstrate PHA-L, tyrosine hydroxylase, dopamine beta-hydroxylase, phenylethanolamine-N-methyltr

155 Brainstem sections were stained for c-Fos, dopamine beta-hydroxylase, phenylethanolamine-N-methyltr

156 ted by tyrosine hydroxylase-positive but not dopamine-beta-hydroxylase-positive fibers, suggesting do

157 ic neurons were in close proximity to single dopamine-beta-hydroxylase-positive varicosities, others,

158 mid inhibits cAMP-mediated expression of the dopamine beta-hydroxylase promoter construct in PC12 and

159 ediated regulation of transcription from the dopamine beta-hydroxylase promoter is mediated by the AP

160 Transgenic mice were created using the dopamine beta-hydroxylase promoter to direct expression

161 t then reconverge on a single element in the dopamine beta-hydroxylase promoter to elicit activation

162 overexpress galanin under the control of the dopamine beta-hydroxylase promoter to study the neuroche

163 SHP-2 mutant under the control of the human dopamine beta-hydroxylase promoter.

164 d from neonatal lethality by expression of a dopamine beta-hydroxylase promoter/ET(B) receptor transg

165 ce that overexpress the galanin gene under a dopamine-beta-hydroxylase promoter (GalOE).

166 activated H-Ras in transgenic mice using the dopamine-beta-hydroxylase promoter, which directs expres

167 reen fluorescent protein under an artificial dopamine beta-hydroxylase (PRSx8) promoter to trace the

168 e spatiotemporal expression of TH, 5-HT, and dopamine beta hydroxylase reactivity, we determined that

169 Immunostaining for dopamine beta-hydroxylase revealed fibers within dopamin

170 ntracerebroventricularly with saline or anti-dopamine-beta-hydroxylase-saporin, a toxin that destroys

171 Intracerebroventricular anti-dopamine beta-hydroxylase/saporin, a treatment that dest

172 mpensatory endocytosis assessed by measuring dopamine-beta-hydroxylase (secretory granule membrane) i

173 iosynthetic enzymes tyrosine hydroxylase and dopamine beta-hydroxylase, suggesting a role for ARIX in

174 tained for tyrosine hydroxylase, but not for dopamine-beta-hydroxylase, suggesting that these axonal

175 s of co-localization of immunoreactivity for dopamine beta-hydroxylase (the synthetic enzyme for nora

176 We used mice lacking the gene coding for dopamine beta-hydroxylase, the enzyme responsible for sy

177 s transcripts encoding NET, NET protein, and dopamine beta-hydroxylase; these neurons lack tyrosine h

178 kers, compared with tyrosine hydroxylase and dopamine beta-hydroxylase, to reflect the extent of adre

179 ious studies indicating direct activation of dopamine beta-hydroxylase transcription by Phox2a/2b, th

180 2 and regulation of tyrosine hydroxylase and dopamine beta-hydroxylase transcription was confirmed in

181 NE and dopamine beta-hydroxylase were increased by 3.8- and 10.

182 ies against 5-HT and the NA precursor enzyme dopamine beta-hydroxylase were utilized to examine the d

183 econd key noradrenergic biosynthetic enzyme, dopamine beta-hydroxylase, which is instead regulated by